The global antisense oligonucleotides market, valued at USD 5.78 billion in 2025, is projected to reach USD 6.31 billion in 2026 and USD 8.57 billion by 2035, with a 8.0% CAGR during the forecast period 2026 to 2035. Since the approval of Vitravene™ (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven antisense oligonucleotides drugs, based on such molecules, that are co...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The cGAS STING pathway market is estimated to be worth $305 million in 2020 and is expected to grow at CAGR of 25% during the forecast period. In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. In fact, more than 50 experimental interventions based on this relatively novel concept are currently being developed for the treatment of oncological, autoimmune and inflammatory disorders....

The single cell sequencing market is estimated to be worth $1,387 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period. Over the years, technological advances in the field of genomics have enabled pharma companies to adopt a more personalized and targeted approach to drug / therapy development. In fact, the cost of sequencing a single genome has dropped from USD ~3 billion (Human Genome Project 1990) to USD 1,000 (Illumina sequencing k...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The intranasal and inhaled drug development market is estimated to be worth $5.5 billion in 2020 and is expected to grow at CAGR of 7.6% during the forecast period. Over the past few decades, the prevalence of respiratory disorders has been increasing at an alarming rate. In fact, each year around 7 million deaths are attributed to respiratory disorders caused by air pollution, worldwide. It is also important to note that, as of April 2020, an estimated 330 million individuals are suffering fro...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The drug repurposing market is estimated to be worth $313 million in 2020 and is expected to grow at CAGR of 14.7% during the forecast period. Of late, the repurposing of marketed / shelved / pipeline candidates for the treatment of diseases different from what they were originally developed for, has emerged as a viable business strategy. In fact, of 28 drugs (including both novel and repurposed) approved by the USFDA in the first quarter of 2020, 12 were repurposed drugs. Further, it is estimat...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment about the drug

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Pemphigus vulgaris, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030. It features an in-depth analysis, highlighting the current treatment pract...

This report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Neuromyelitis optica. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the drug

This report provides an informed opinion on the likely adoption of therapeutics designed to treat peanut allergy. It features an in-depth analysis, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape and its growth prospects over the coming years, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an informed opinion on the likely adoption of therapeutics designed to treat multi-drug resistant tuberculosis. It features an in-depth analysis, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product